Shares of Novartis AG (NYSE:NVS) have received a consensus recommendation of “Hold” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $85.39.
A number of research firms have recently issued reports on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th. UBS reissued a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th.
Several hedge funds and other institutional investors have recently bought and sold shares of NVS. Wealthcare Advisory Partners LLC acquired a new position in Novartis in the third quarter worth approximately $106,000. Pinnacle Wealth Planning Services Inc. acquired a new position in Novartis in the fourth quarter worth approximately $113,000. Calton & Associates Inc. acquired a new position in Novartis in the fourth quarter worth approximately $118,000. SeaCrest Wealth Management LLC acquired a new position in Novartis in the fourth quarter worth approximately $124,000. Finally, Trustcore Financial Services LLC acquired a new position in Novartis in the fourth quarter worth approximately $178,000. 10.80% of the stock is owned by institutional investors and hedge funds.
Novartis (NYSE NVS) traded up $0.25 during mid-day trading on Friday, reaching $82.06. 1,994,543 shares of the company’s stock were exchanged, compared to its average volume of 1,475,735. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31. Novartis has a 52 week low of $72.67 and a 52 week high of $94.19. The stock has a market capitalization of $190,170.44, a price-to-earnings ratio of 25.25, a PEG ratio of 1.91 and a beta of 0.78.
Novartis (NYSE:NVS) last posted its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.04. The company had revenue of $12.92 billion during the quarter, compared to analyst estimates of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 earnings per share. analysts forecast that Novartis will post 5.36 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Novartis AG (NVS) Receives Consensus Recommendation of “Hold” from Brokerages” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/18/novartis-ag-nvs-receives-consensus-recommendation-of-hold-from-brokerages.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.